These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9109527)

  • 1. Time course and regional basis of Pb-induced changes in MK-801 binding: reversal by chronic treatment with the dopamine agonist apomorphine but not the D1 agonist SKF-82958.
    Cory-Slechta DA; McCoy L; Richfield EK
    J Neurochem; 1997 May; 68(5):2012-23. PubMed ID: 9109527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preferential vulnerability of nucleus accumbens dopamine binding sites to low-level lead exposure: time course of effects and interactions with chronic dopamine agonist treatments.
    Pokora MJ; Richfield EK; Cory-Slechta DA
    J Neurochem; 1996 Oct; 67(4):1540-50. PubMed ID: 8858938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional decreases in alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid ([3H]AMPA) and 6-[3H]cyano-7-nitroquinoxaline-2,3-dione ([3H]CNQX) binding in response to chronic low-level lead exposure: reversal versus potentiation by chronic dopamine agonist treatment.
    McCoy L; Richfield EK; Cory-Slechta DA
    J Neurochem; 1997 Dec; 69(6):2466-76. PubMed ID: 9375679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low level lead exposure increases sensitivity to the stimulus properties of dopamine D1 and D2 agonists.
    Cory-Slechta DA; Widzowski DV
    Brain Res; 1991 Jul; 553(1):65-74. PubMed ID: 1681979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lead-induced decrements in waiting behavior: involvement of D2-like dopamine receptors.
    Brockel BJ; Cory-Slechta DA
    Pharmacol Biochem Behav; 1999 Jul; 63(3):423-34. PubMed ID: 10418784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MK-801 reverses effects of chronic levodopa on D1 and D2 dopamine agonist-induced rotational behavior.
    Boldry RC; Papa SM; Kask AM; Chase TN
    Brain Res; 1995 Sep; 692(1-2):259-64. PubMed ID: 8548312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lead-induced changes in dopamine D1 sensitivity: modulation by drug discrimination training.
    Cory-Slechta DA; Pokora MJ; Fox RA; O'Mara DJ
    Neurotoxicology; 1996; 17(2):445-57. PubMed ID: 8856740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of metyrapone on MK-801-induced alterations in the rat dopamine D1 receptors.
    Czyrak A; Maćkowiak M; Fijał K; Chocyk A; Wedzony K
    Pol J Pharmacol; 1997; 49(5):305-16. PubMed ID: 9566029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postnatal lead exposure induces supersensitivity to the stimulus properties of a D2-D3 agonist.
    Cory-Slechta DA; Pokora MJ; Widzowski DV
    Brain Res; 1992 Dec; 598(1-2):162-72. PubMed ID: 1362517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of NMDA and MK-801 injected into the substantia nigra pars reticulata on jaw movements evoked by dopamine D1-/D2 receptor stimulation in the ventrolateral striatum: studies in freely moving rats.
    Uchida T; Lee J; Fujita S; Kiguchi M; Matsumoto M; Oi Y; Gionhaku N; Koshikawa N
    Methods Find Exp Clin Pharmacol; 2005; 27(1):31-7. PubMed ID: 15834457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in mesocorticolimbic dopamine and D1/D2 receptor levels after low level lead exposure: a time course study.
    Gedeon Y; Ramesh GT; Wellman PJ; Jadhav AL
    Toxicol Lett; 2001 Sep; 123(2-3):217-26. PubMed ID: 11641049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic control of angiotensin II-induced vasopressin secretion in vitro.
    Rossi NF
    Am J Physiol; 1998 Oct; 275(4):E687-93. PubMed ID: 9755089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MK-801 reverses Fos expression induced by the full dopamine D1 receptor agonist SKF-82958 in the rat striatum.
    Nakazato E; Ohno M; Watanabe S
    Eur J Pharmacol; 1998 Jan; 342(2-3):209-12. PubMed ID: 9548387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of dopamine agonists on fixed interval schedule-controlled behavior are selectively altered by low-level lead exposure.
    Cory-Slechta DA; Pokora MJ; Preston RA
    Neurotoxicol Teratol; 1996; 18(5):565-75. PubMed ID: 8888021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1- and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding.
    Breese GR; Duncan GE; Napier TC; Bondy SC; Iorio LC; Mueller RA
    J Pharmacol Exp Ther; 1987 Jan; 240(1):167-76. PubMed ID: 3100767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-level lead exposure selectively enhances dopamine overflow in nucleus accumbens: an in vivo electrochemistry time course assessment.
    Zuch CL; O'Mara DJ; Cory-Slechta DA
    Toxicol Appl Pharmacol; 1998 May; 150(1):174-85. PubMed ID: 9630467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chronic treatment with dizocilpine (MK-801) on the behavioral response to dopamine receptor agonists in the rat.
    Dall'Olio R; Gandolfi O; Montanaro N
    Psychopharmacology (Berl); 1992; 107(4):591-4. PubMed ID: 1534911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of individual and concurrent stimulation of striatal D1 and D2 dopamine receptors on electrophysiological and behavioral output from rat basal ganglia.
    Waszczak BL; Martin LP; Finlay HE; Zahr N; Stellar JR
    J Pharmacol Exp Ther; 2002 Mar; 300(3):850-61. PubMed ID: 11861790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.